Onkologie. 2009:3(4):214-218

Mannose binding lectin in pediatric oncology patients

MUDr. Peter Múdry¹, Michal Kýr¹, Tomáš Freiberger², Jiří Jarkovský³, prof. MUDr. Jaroslav Štěrba Ph.D¹, Jitka Chumchalová⁴

¹ Klinika dětské onkologie LF MU a FN, Brno

² Genetická laboratoř Centra kardiovaskulární a transplantační chirurgie, Brno

³ Centrum biostatistiky a analýz, Masarykova univerzita, Brno

⁴ Interní hematoonkologická klinika LF MU a FN Brno

Mannose binding lectin, a serum protein produced in liver as acute phase reactant, represents a substantial part of innate immune

res ponse. Several polymorphisms in MBL encoding gene MBL-2 are known thus expressing MBL deficiency (MBLD). Well known are

worse coursies of neonatal sepsis or infections in cystic fibrosis patients with MBLD. During last decade, attention is focused also to

infections in oncology patients with chemotherapy induced immunodeficiency. The results are rather controversial. Further research

is done on field of cancer ethiology in MBLD patients and some papers point an association of MBLD and several cancers. Infusion

therapy with MBL is possible. New trials and experiments are necessary to define target population for MBL substitution therapy.

This paper analyzes published experiences with MBLD in pediatric oncology patients and we report here also some own results of

MBLD research.

Keywords: mannose binding lectin, febrile neutropenia, acute lymphoblastic leukemia, neuroblastoma, Ewing sarcoma/PNET, child.

Published: November 1, 2009  Show citation